Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01326702 · OUTCOME

Progression-free Survival Using RECIST Version 1.1 (Phase IIa)

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · Source last updated 2019-12-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
Full Range
Time frame
2 years

What was measured

Kaplan-Meier estimates will be calculated and log-rank tests will be employed when certain comparisons are needed. Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.

Analysis population: Participants treated on Dose Level 7 make up the cohort expansion of VBR in participants with CD20+ B-cell lymphoma.

Groups in this outcome

All Study Participants

Dose Level 7; Bendamustine 90mg/m2, ABT-888 400mg BID

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Study Participants7

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
All Study Participants14.2Not reported220.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2
        upper Limit
        20.1
        value
        14.2
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    units
    Participants
description
Kaplan-Meier estimates will be calculated and log-rank tests will be employed when certain comparisons are needed. Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.
dispersion Type
Full Range
groups
  1. description
    Dose Level 7; Bendamustine 90mg/m2, ABT-888 400mg BID
    id
    OG000
    title
    All Study Participants
param Type
MEDIAN
population Description
Participants treated on Dose Level 7 make up the cohort expansion of VBR in participants with CD20+ B-cell lymphoma.
reporting Status
POSTED
time Frame
2 years
title
Progression-free Survival Using RECIST Version 1.1 (Phase IIa)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice